Development of a Next-Generation Dual Knock-Out TIL Product GT300 with AaCas12bMax Nuclease

Time: 12:00 pm
day: Conference Day One R&D Track AM

Details:

  • GT300 is a CRISPR/AaCas12bMax engineered TIL product with KO of two key immunoregulatory targets that reverses TIL exhaustion and overcomes the harsh TME
  • A safety assessment framework was developed aligning with FDA guidelines, incorporating orthogonal methodologies for off-target and chromosomal structural variation assessment
  • Comparative analysis of SpCas9- versus AaCas12bMAXedited TIL products, including on-target efficiency, safety profiling, functional phenotyping, and mechanistic interrogation

Speakers:

Jingwei Sun
Jingwei Sun Dr. Jingwei Sun is the Vice President of Research and Discovery at Grit Biotechnology. She received her Ph.D. and completed her postdoctoral training in Immunobiology Read more